Innovative Health Diagnostics Announces New Direct-to-Consumer Tests in Women’s Health and COVID-19

13 Sep 2022
www.biospace.com
VaccineAntibody
The clinical laboratory now offers an Anti-Mullerian Hormone (AMH) test and COVID-19 Neutralizing Antibody (CNAB) test, increasing access to convenient, reliable at-home testing in women’s health and COVID-19 prevention IRVINE, Calif.--(BUSINESS WIRE)-- Innovative Health Diagnostics (IHD), a CLIA- and FDA-certified lab that empowers every person by providing access to accurate, clinical testing when and where it matters most, announced today that it now offers two at-home diagnostic tests for public purchase online. IHD now offers two of its leading at-home tests for public purchase directly on the company’s website: the Anti-Mullerian Hormone (AMH) test and COVID-19 Neutralizing Antibody (CNAB) test. The clinical laboratory is known for its reliable line of over 70 diagnostic tests and ability to turn around fast results to its partners – healthcare clinics/practices, corporations, and independent physicians. IHD’s AMH test measures the level of AMH in a person’s body and provides a range for comparison. The test is generally a good indicator of a person’s ovarian reserve. The test costs $99. IHD’s CNAB test detects SARS-COV-2 neutralizing antibodies that a person’s body produces in response to a previous exposure to COVID-19 – either from infection or a vaccine. The test can be taken at home to better understand a person’s long-term immunity, allowing one to take necessary precautions. The test costs $85. “We have been providing important and reliable tests to healthcare providers and business partners for years so that they can offer end-to-end testing solutions with quick results,” said David White, IHD CEO and Co-Founder. “We are so pleased to start offering some of these same diagnostic solutions to the general public directly from our lab and into one’s home through a simple online transaction. This helps extend our mission to provide access to accurate clinical testing when and where it matters most.” IHD serves as a trusted resource for patients seeking to get their health questions answered quickly and accurately. The AMH and CNAB tests are the first two direct-to-consumer tests that IHD offers, with plans for future expansion of more of the company’s line of at-home tests to come. About Innovative Health Diagnostics Innovative Health Diagnostics (IHD) empowers every person by providing access to accurate, clinical testing, when and where it matters most. IHD services also include fertility and in vitro fertilization (IVF) testing; FDA donor testing for families completing surrogacies; and COVID-19 polymerase chain reaction (PCR) and antibody testing. A nimble, collaborative partner, IHD operates with the patient in mind at all times, offering the highest standards of integrity and service, quick turnaround times, and affordability. To learn more, please visit ihdlab.com or follow us on LinkedIn, Twitter, Facebook and Instagram. View source version on businesswire.com: Contacts IHD Media Contact: Nicole Estrin IHD@antennagroup.com 412-491-1043 Source: Innovative Health Diagnostics View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.